Green Thumb Industries (GTBIF) Depreciation & Amortization (CF) (2019 - 2026)
Green Thumb Industries (GTBIF) posted Depreciation & Amortization (CF) of $32.4 million for Q1 2026, down 42.41% on a QoQ basis from $56.3 million in Q4 2025, and up 10.21% year-over-year from $29.4 million in Q1 2025.
Green Thumb Industries (GTBIF) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Green Thumb Industries' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $32.4 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 10.21% year-over-year to $32.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.5 million (up 29.26% YoY) and the FY2025 annual result came in at $145.4 million, up 28.48% from the prior year.
- Depreciation & Amortization (CF) was $32.4 million for Q1 2026 at Green Thumb Industries, down from $56.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $56.3 million in Q4 2025 and bottomed at $23.0 million in Q1 2022.
- A 5-year average of $28.7 million and a median of $27.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) climbed 0.15% — and 2025, when it surged 94.37%.
- Green Thumb Industries' Depreciation & Amortization (CF) stood at $25.0 million in 2022, then grew by 9.89% to $27.4 million in 2023, then climbed by 5.58% to $29.0 million in 2024, then jumped by 94.37% to $56.3 million in 2025, then plunged by 42.41% to $32.4 million in 2026.
- Business Quant data shows GTBIF's Depreciation & Amortization (CF) at $32.4 million in Q1 2026, $56.3 million in Q4 2025, and $30.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 32.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.41 Mn |
| Mar 31, 2026 | 32.41 Mn |
| Dec 31, 2025 | 56.29 Mn |
| Dec 31, 2025 | 56.29 Mn |
| Sep 30, 2025 | 30.08 Mn |
| Sep 30, 2025 | 30.08 Mn |
| Jun 30, 2025 | 29.67 Mn |
| Jun 30, 2025 | 29.67 Mn |
| Mar 31, 2025 | 29.41 Mn |
| Mar 31, 2025 | 29.41 Mn |
| Dec 31, 2024 | 28.96 Mn |
| Dec 31, 2024 | 28.96 Mn |
| Sep 30, 2024 | 28.49 Mn |
| Sep 30, 2024 | 28.49 Mn |
| Jun 30, 2024 | 27.99 Mn |
| Jun 30, 2024 | 27.99 Mn |
| Mar 31, 2024 | 27.78 Mn |
| Mar 31, 2024 | 27.78 Mn |
| Dec 31, 2023 | 27.43 Mn |
| Dec 31, 2023 | 27.43 Mn |